TG Therapeutics Financials - Benzinga

TG Therapeutics Inc

TGTXNASDAQ

Trade with Public

Trade with Public

$57.40

0.240.42%

Últ. Act.: Sep 22, 9:15 AM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

TG Therapeutics Financials

TG Therapeutics (TGTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
TG Therapeutics Raises FY2026 Sales Guidance from $925.000M to $950.000M vs $942.370M Est

TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $925.000 million to $950.000 million vs $942.370 million estimate.

Benzinga Newsdesk

PRO
TG Therapeutics Q2 EPS $0.05 Misses $0.33 Estimate, Sales $240.335M Beat $229.721M Estimate

TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.33 by 84.85 percent. This is a 70.59 percent decrease over earnings of $0.17 per share from

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
TG Therapeutics Q1 Adj. EPS $0.18 Misses $0.30 Estimate, Sales $204.918M Beat $196.814M Estimate

TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.30 by 40 percent. This is a 500 percent increase over earnings of $0.03 per share from the

Benzinga Newsdesk

PRO
TG Therapeutics Raises FY2026 Sales Guidance from $875.000M-$900.000M to $925.000M vs $906.021M Est

TG Therapeutics (NASDAQ:TGTX) raises FY2026 sales outlook from $875.000 million-$900.000 million to $925.000 million vs $906.021 million estimate.

Benzinga Newsdesk

TG Therapeutics Q4 Earnings Assessment

Benzinga Insights

© 2026 Benzinga | All Rights Reserved